Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using Toll-like receptor 7 agonist imiquimod as vaccine adjuvant

T cell-mediated immunity to microbes and to cancer can be enhanced by the activation of dendritic cells (DCs) via Toll-like receptors (TLRs). In this study, we evaluated the safety and feasibility of topical imiquimod, a TLR7 agonist, in a series of vaccinations (26) proteins,(27) and DNA, (28, 29)...

詳細記述

保存先:
書誌詳細
主要な著者: Adams, Sylvia, O'Neill, David W., Nonaka, Daisuke, Hardin, Elizabeth, Chiriboga, Luis, Siu, Kimberly, Cruz, Crystal M., Angiulli, Angelica, Angiulli, Francesca, Ritter, Erika, Holman, Rose Marie, Shapiro, Richard L., Berman, Russell S., Berner, Natalie, Shao, Yongzhao, Manches, Olivier, Pan, Linda, Venhaus, Ralph R., Hoffman, Eric W., Jungbluth, Achim, Gnjatic, Sacha, Old, Lloyd, Pavlick, Anna C., Bhardwaj, Nina
フォーマット: Artigo
言語:Inglês
出版事項: 2008
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC2583094/
https://ncbi.nlm.nih.gov/pubmed/18566444
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料